{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:15:34Z","timestamp":1749010534507,"version":"3.41.0"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1097\/cm9.0000000000001695","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T23:00:19Z","timestamp":1631314819000},"page":"250-252","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma"],"prefix":"10.1097","volume":"135","author":[{"given":"Tiantao","family":"Gao","sequence":"first","affiliation":[{"name":"Clinical Trial Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Natural Products, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Shen","sequence":"additional","affiliation":[{"name":"Clinical Trial Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Luo","sequence":"additional","affiliation":[{"name":"Clinical Trial Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Feng","sequence":"additional","affiliation":[{"name":"Clinical Trial Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Miao","sequence":"additional","affiliation":[{"name":"Clinical Trial Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zheng","sequence":"additional","affiliation":[{"name":"Clinical Trial Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicinal Natural Products, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Xiang","sequence":"additional","affiliation":[{"name":"Clinical Trial Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12185-010-0624-7","article-title":"Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed\/refractory multiple myeloma","volume":"92","author":"Iida","year":"2010","journal-title":"Int J Hematol"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40262-016-0432-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of lenalidomide","volume":"56","author":"Chen","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000477792","article-title":"Realistic lenalidomide dose adjustment strategy for transplant-ineligible elderly patients with relapsed\/refractory multiple myeloma: Japanese real-world experience","volume":"138","author":"Nakaya","year":"2017","journal-title":"Acta Haematol"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O\u2019Donnell","year":"2018","journal-title":"Br J Haematol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:04:36Z","timestamp":1748977476000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":5,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001695","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"type":"print","value":"0366-6999"},{"type":"electronic","value":"2542-5641"}],"subject":[],"published":{"date-parts":[[2021,9,9]]}}}